«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年04期

页码:

316-319

栏目:

基础医学

出版日期:

2019-07-20

文章信息/Info

Title:

Action mechanism of Shenxiaogualousan in treatment of breast cancer by network pharmacology method

文章编号:

1006-8147(2019)04-0316-04

作者:

付精精; 吴雄志

（天津医科大学肿瘤医院中西医结合科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060）

Author(s):

FU Jing-jing;  WU Xiong-zhi

(Department of Integrated Traditional Chinese and Western Medicine,Cancer Institute Hopital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060,China)

关键词:

神效瓜蒌散; 乳腺癌; 网络药理学; ER

Keywords:

Shenxiaogualousan;  breast cancer;  network pharmacology;  ER

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：通过网络药理学探究神效瓜蒌散治疗乳腺癌的机制。方法：设置不同剂量神效瓜蒌散组，对乳腺癌细胞SKBR-3进行台盼蓝染色法、MTS试验、划痕实验等体外实验验证其治疗乳腺癌的作用，通过网络药理学构建有效成分-作用靶点网络,预测神效瓜蒌散作用于乳腺癌的机制，最后通过Western blot实验验证预测。结果：神效瓜蒌散能够在体外抑制乳腺癌细胞SKBR-3的增殖和迁移，通过网络药理学预测神效瓜蒌散可能通过ER、HSP90等靶点作用于乳腺癌发挥其抗肿瘤作用，通过 Western blot 观察到神效瓜蒌散作用的乳腺癌细胞SKBR-3的ERα表达下降。结论：神效瓜蒌散可能主要通过抑制ER内分泌通路治疗乳腺癌。

Abstract:

Objective: To explore the Shenxiaogualousan mechanism for the treatment of breast cancer by the network pharmacology and in vitro experiments. Methods: Shenxiaogualousan groups given different dosages were established in the present study. Trypan blue staining, MTS test, scratch test and other in vitro tests were used to verify the effect of Shenxiaogualousan on breast cancer cell line SKBR-3. Furthermore, the mechanism of Shenxiaogualousan in breast cancer was predicted by constructing an active component-action target network through network pharmacology, followed by verification using western blot. Results: The effective Shenxiaogualousan could inhibit the proliferation and migration of breast cancer cell line SKBR-3 in vitro. Network pharmacology predicted that the effective Shenxiaogualousan could have anti-tumor effect on breast cancer through ER, HSP90 and other targets. Furthermore, western blot results showed that the expression of ERα was decreased in SKBR-3 cells after treated with the effective Shenxiaogualousan. Conclusion: The effective Shenxiaogualousan may have a role in the treatment of breast cancer through the inhibition of ER endocrine pathways.

参考文献/References:

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):359
[2] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics 2012[J]. CA Cancer J Clin, 2015, 65(2):87
[3] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115
[4] Siersbaek R, Kumar S, Carroll J S. Signaling pathways and steroid receptors modulating estrogen receptor a function in breast cancer[J]. Genes Dev, 2018, 32(17/18):1141
[5] Qi F H, Zhao L, Zhou A Y, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer[J]. Biosci Trends, 2015, 9(1):16
[6] Li X, Yang G, Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese[J]. PLoS One, 2013, 8(4):60338
[7] Yang X E, Hao J, Zhu C H, et al. Survival benefits of western and traditional Chinese medicine treatment for patients with pancreatic cancer[J]. Medicine, 2015, 94(26):1008
[8] 张莹,韦佳慧,张成玲,等.基于网络药理学的加味佛手散抑制子宫内膜侵袭转移机制研究[J].药学学报,2018,53(9):1398
[9] Ning K, Zhao X, Poetsch A, et al. Computational molecular networks and network pharmacology[J]. Biomed Res Int, 2017, 2017(1): 7573904
[10] Wang Y, Lin W, Li C, et al. Multipronged therapeutic effects of Chinese herbal medicine Qishenyiqi in the treatment of acute myocardial infarction[J]. Front Pharmacol, 2017, 8(2):98
[11] Gao L, Wang X D, Niu Y Y, et al. Molecular targets of Chinese herbs:a clinical study of hepatoma based on network pharmacology[J]. Sci Rep, 2016, 6(4):24944
[12] 杨洁, 韩为东, 赵亚力.雌激素与乳腺癌[J].现代肿瘤医学, 2007, 15(3):431
[13] 刘晓霞,翟曜耀,赵越.雌激素受体ERα的功能调控及相关疾病的研究进展[J].中国细胞生物学学报,2011,33(1):65
[14] Rochelle B, Luke W. Altered Hsp90 function in cancer:A unique therapeutic opportunity[J]. Mol Cancer Ther, 2004, 3(8):1021
[15] 张柯基,张凤春.乳腺癌ER信号途径中HSP90作用之研究进展-一种乳腺癌新的靶向治疗思路的理论基础[J].现代肿瘤医学,2007,15(2):270
[16] Pick E, Kluger Y, Giltnane J M, et al. High HSP90 expression is associated with decreased survival in breast cancer[J]. Cancer Res, 2007, 67(7):2932
[17] 杨新苗,洪小南,胡夕春.环氧化酶-2与乳腺癌关系的研究进展[J].中国癌症杂志,2004,14(6):80
[18] 林艳,匡文斌,吴碧涛,等.肝细胞生长因子通过上调环氧合酶2表达增强乳腺癌细胞的侵袭能力[J].肿瘤,2015,35(7):732
[19] Qin G, Xu F, Qin T, et al. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway[J]. Oncotarget, 2015, 6(39):41794
[20] Harris R E, Chlebowski R T, Jackson R D, et al. Breast cancer and nonsteroidal anti-imflammatory drugs:prodpective results from the Women’s Health Initiative[J]. Cancer Res, 2003, 63(18):6096

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(04):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(04):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(04):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(04):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(04):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(04):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(04):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(04):466.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金资助项目（81473441）
作者简介 付精精（1992-），女，硕士在读，研究方向：肿瘤学；通信作者：吴雄志，E-mail:13702062585@163.com。

常用功能

更新日期/Last Update: 2019-08-28